Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine

Research output: Contribution to journalArticle

Abstract

Due to their ability to effectively downregulate the expression of target genes, small interfering RNA (siRNA) have emerged as promising candidates for precision medicine in cancer. Although some siRNA-based treatments have advanced to clinical trials, challenges such as poor stability during circulation, and less than optimal pharmacokinetics and biodistribution of siRNA in vivo present barriers to the systemic delivery of siRNA. In recent years, theranostic nanomedicine integrating siRNA delivery has attracted significant attention for precision medicine. Theranostic nanomedicine takes advantage of the high capacity of nanoplatforms to ferry cargo with imaging and therapeutic capabilities. These theranostic nanoplatforms have the potential to play a major role in gene specific treatments. Here we have reviewed recent advances in the use of theranostic nanoplatforms to deliver siRNA, and discussed the opportunities as well as challenges associated with this exciting technology. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

Original languageEnglish (US)
Article numbere1595
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Nanomedicine
Medical nanotechnology
RNA
Nanoparticles
Small Interfering RNA
Neoplasms
Precision Medicine
Medicine
Genes
Technology
Imaging techniques
Pharmacokinetics
Nanostructures
Drug Discovery
Therapeutics
Nanostructured materials
Theranostic Nanomedicine
Down-Regulation
Clinical Trials
Gene Expression

Keywords

  • cancer
  • molecular imaging
  • nanomedicine
  • siRNA
  • theranostics

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

@article{c608897c228247a69aab2ace7757d21a,
title = "Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine",
abstract = "Due to their ability to effectively downregulate the expression of target genes, small interfering RNA (siRNA) have emerged as promising candidates for precision medicine in cancer. Although some siRNA-based treatments have advanced to clinical trials, challenges such as poor stability during circulation, and less than optimal pharmacokinetics and biodistribution of siRNA in vivo present barriers to the systemic delivery of siRNA. In recent years, theranostic nanomedicine integrating siRNA delivery has attracted significant attention for precision medicine. Theranostic nanomedicine takes advantage of the high capacity of nanoplatforms to ferry cargo with imaging and therapeutic capabilities. These theranostic nanoplatforms have the potential to play a major role in gene specific treatments. Here we have reviewed recent advances in the use of theranostic nanoplatforms to deliver siRNA, and discussed the opportunities as well as challenges associated with this exciting technology. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanomaterials and Implants.",
keywords = "cancer, molecular imaging, nanomedicine, siRNA, theranostics",
author = "Zhihang Chen and Balaji Krishnamachary and Jesus Pachecho-Torres and Penet, {Marie France} and Bhujwalla, {Zaver M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/wnan.1595",
language = "English (US)",
journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",
issn = "1939-0041",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine

AU - Chen, Zhihang

AU - Krishnamachary, Balaji

AU - Pachecho-Torres, Jesus

AU - Penet, Marie France

AU - Bhujwalla, Zaver M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Due to their ability to effectively downregulate the expression of target genes, small interfering RNA (siRNA) have emerged as promising candidates for precision medicine in cancer. Although some siRNA-based treatments have advanced to clinical trials, challenges such as poor stability during circulation, and less than optimal pharmacokinetics and biodistribution of siRNA in vivo present barriers to the systemic delivery of siRNA. In recent years, theranostic nanomedicine integrating siRNA delivery has attracted significant attention for precision medicine. Theranostic nanomedicine takes advantage of the high capacity of nanoplatforms to ferry cargo with imaging and therapeutic capabilities. These theranostic nanoplatforms have the potential to play a major role in gene specific treatments. Here we have reviewed recent advances in the use of theranostic nanoplatforms to deliver siRNA, and discussed the opportunities as well as challenges associated with this exciting technology. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

AB - Due to their ability to effectively downregulate the expression of target genes, small interfering RNA (siRNA) have emerged as promising candidates for precision medicine in cancer. Although some siRNA-based treatments have advanced to clinical trials, challenges such as poor stability during circulation, and less than optimal pharmacokinetics and biodistribution of siRNA in vivo present barriers to the systemic delivery of siRNA. In recent years, theranostic nanomedicine integrating siRNA delivery has attracted significant attention for precision medicine. Theranostic nanomedicine takes advantage of the high capacity of nanoplatforms to ferry cargo with imaging and therapeutic capabilities. These theranostic nanoplatforms have the potential to play a major role in gene specific treatments. Here we have reviewed recent advances in the use of theranostic nanoplatforms to deliver siRNA, and discussed the opportunities as well as challenges associated with this exciting technology. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanomaterials and Implants.

KW - cancer

KW - molecular imaging

KW - nanomedicine

KW - siRNA

KW - theranostics

UR - http://www.scopus.com/inward/record.url?scp=85074669081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074669081&partnerID=8YFLogxK

U2 - 10.1002/wnan.1595

DO - 10.1002/wnan.1595

M3 - Article

C2 - 31642207

AN - SCOPUS:85074669081

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

SN - 1939-0041

M1 - e1595

ER -